Vaxcyte (PCVX) Depreciation & Amortization (CF) (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $2.9 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $2.9 million, changed 0.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.4 million (up 82.89% YoY), and the FY2025 annual result was $16.4 million, up 134.13% from the prior year.
• Depreciation & Amortization (CF) slipped to $2.9 million in Q1 2026 per PCVX's latest filing, from $7.5 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $7.5 million in Q4 2025 and troughed at $582000.0 in Q1 2022.
• A 5-year average of $1.9 million and a median of $999000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) decreased 7.4% in 2023, then jumped 222.52% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $959000.0 in 2022, then fell by 7.4% to $888000.0 in 2023, then jumped by 222.52% to $2.9 million in 2024, then soared by 161.77% to $7.5 million in 2025, then slumped by 60.69% to $2.9 million in 2026.
• Business Quant data shows PCVX's Depreciation & Amortization (CF) at $2.9 million in Q1 2026, $7.5 million in Q4 2025, and $3.1 million in Q3 2025.